| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.17 | 1e-06 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.18 | 3e-06 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.23 | 2e-05 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-05 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.21 | 9e-05 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0001 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0001 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.0003 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.23 | 0.0003 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0003 |